Biopharmaceuticals have revolutionized modern medicine and given new hope for those diagnosed with cancer and other devastating chronic diseases. Monoclonal antibodies remain the most advanced and effective therapeutics for such diseases to date. Biosimilars promise to make these cutting-edge drugs more accessible, offering to prolong and improve the lives of even a greater number of patients across the globe.

Here at BioXpress we create biosimilars of uncompromising quality. We develop in Switzerland and manufacture for distribution worldwide.

BioXpress was founded in Geneva by the industry leaders in cell-line development and analytical characterization and has built a team of experts in the development of biopharmaceuticals and biosimilars, their manufacturing, characterization, clinical and regulatory development. Our partnership with Selexis ensures highest standards in cell-line development, coupled with a collaboration with SGS for analytics, and priority access to laboratories and a CMO in Switzerland for optimal process development and GMP manufacturing so that the development of our biosimilars can be managed in a cost-effective and streamlined process.

Become a partner, explore the opportunities that our pipeline could bring to your company. Our industry veterans are here to support you from generating the optimal cell-line to the optimal regulatory development path and beyond. Contact us today. Because, together, we are stronger.